Novel Kinase Inhibitors for the Treatment of Autoimmune and Inflammatory Diseases
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 2089
Special Issue Editor
Interests: macromolecular crystallography; small molecule crystallography; structural enzymology; protein-ligand interactions; antibiotic resistance; cellular methylation; S-adenosyl-L-homocysteine hydrolase
Special Issue Information
Dear Colleagues,
Non-controlled inflammation response and the dysregulation of the immune system may lead to serious issues related to various pathological processes in humans. Chronic inflammation is directly associated with numerous diseases, including asthma, Crohn’s disease, psoriasis or rheumatoid arthritis. On the other hand, approximately 100 autoimmune diseases, such as multiple sclerosis, type 1 diabetes or some nephropathies, have been described so far. Herein, the inflammation process is activated and, in turn, an individual’s own tissues are damaged due to an autoimmune response. Unsurprisingly, the main therapies against autoimmune and inflammatory diseases target kinases involved in disturbed inflammation processes. Therapeutics approved and used for treating these diseases usually target two types of enzymes: the non-receptor tyrosine protein (TYK2) and Janus (JAK) kinases. However, there has been significant progress in developing new kinase inhibitors, which also target other kinases involved in the inflammatory processes, highlighting the scientific importance of this topic.
The Special Issue aims to collect suitable research articles, communications, reviews or perspective articles related to the title “Novel Kinase Inhibitors for the Treatment of Autoimmune and Inflammatory Diseases” to emphasize the recent advances in the development of inhibitors that target enzymes involved in pathological processes. This Special Issue will focus on, but is not limited to, the biological, chemical, structural and pharmacological aspects related to developing novel immunosuppressants and anti-inflammatory drugs.
Dr. Krzysztof Brzeziński
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kinase
- enzyme inhibition
- drug design
- organic synthesis
- structural biology
- medicinal chemistry
- structure-activity relationship
- enzyme–ligand complex
